01 The pain management therapeutics market is shifting rapidly towards safer, non-opioid treatment options as healthcare providers aim to reduce opioid dependence while improving long-term patient outcomes. It is the first medicine in a new class of pain drugs approved in more than 20 years, highlighting growing investment in innovative pain therapies.Another major trend is the increasing use of multimodal pain management, where physicians combine medicines with physical therapy, nerve stimulation, digital health tools, and behavioural therapies to provide better pain relief while lowering opioid exposure. Artificial intelligence and wearable devices are also being explored to monitor pain patterns and personalise treatment plans for chronic pain patients.Research and investment are increasingly focused on precision medicine, biologics, gene-based therapies, and neuromodulation for conditions such as neuropathic pain, osteoarthritis, and cancer-related pain. Large pharmaceutical companies are strengthening their non-opioid pipelines through acquisitions and collaborations, reflecting confidence in next-generation pain therapeutics. With nearly 50 million adults in the U.S. living with chronic pain, the demand for effective, safer, and personalised pain management therapies is expected to remain strong over the coming years.
01 Rising Prevalence of Chronic Pain and Musculoskeletal Disorders The global pain management therapeutics market is primarily driven by the increasing prevalence of chronic pain conditions, including arthritis, lower back pain, neuropathic pain, migraines, and cancer-related pain. The growing ageing population, sedentary lifestyles, and rising incidence of chronic diseases have significantly increased the demand for effective pain management therapies. Healthcare providers are increasingly adopting advanced therapeutics to improve patients' quality of life while reducing long-term disability.For instance, according to the U.S. Centers for Disease Control and Prevention (CDC), approximately 51.6 million U.S. adults live with chronic pain, while about 17.1 million experience high-impact chronic pain that frequently limits daily activities. This growing patient population continues to drive demand for innovative and long-lasting pain management solutions.
02 Growing Demand for Non-Opioid and Personalised Pain Therapies The market is also witnessing strong growth due to the increasing shift towards non-opioid pain treatments amid concerns over opioid addiction and misuse. At the same time, personalised treatment approaches are gaining traction, allowing clinicians to tailor therapies based on patient-specific conditions and improving clinical outcomes.
01 High Cost of Advanced Pain Management Therapies The high cost of innovative pain therapeutics and advanced medical devices remains a significant barrier to market growth, particularly in low- and middle-income countries. Treatments such as neuromodulation devices, biologics, regenerative therapies, and implantable pain management systems require substantial investment, making them inaccessible for many patients. In addition, long-term treatment, follow-up procedures, and maintenance costs further increase the overall financial burden.For instance, spinal cord stimulation systems commonly cost between $20,000 and $70,000, including device implantation and related medical procedures. Similarly, newly launched non-opioid therapies and advanced biologics often carry premium pricing, limiting their widespread adoption where reimbursement coverage is inadequate.
01 Expansion of Non-Opioid and Precision Pain Therapies The growing demand for safer alternatives to opioids is creating significant opportunities for the pain management therapeutics market. . Advances in artificial intelligence, biomarker-based diagnostics, and personalised treatment approaches are also enabling more targeted pain management strategies, improving patient outcomes and expanding the market's growth potential.For instance, in January 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) by Vertex Pharmaceuticals, the first non-opioid pain medicine with a new mechanism of action approved in more than two decades. The approval highlights the growing industry focus on developing innovative, safer pain therapeutics and is expected to encourage further investment in next-generation pain management solutions.
01 Regulatory Complexity and Limited Access to Advanced Therapies Despite continuous innovation, the market faces significant challenges due to stringent regulatory requirements and unequal access to advanced pain treatments. Novel therapeutics must undergo extensive clinical trials to demonstrate long-term safety and efficacy, resulting in prolonged approval timelines and higher development costs. In addition, reimbursement limitations, high treatment expenses, and shortages of pain management specialists continue to restrict patient access, particularly in developing economies.For instance, implantable pain management technologies such as spinal cord stimulators can cost between $20,000 and $70,000, including implantation procedures, making them inaccessible for many patients without comprehensive insurance coverage. These affordability and reimbursement barriers continue to slow the adoption of advanced pain management therapies worldwide.
May 2026 Medtronic announced plans to acquire SPR Therapeutics to expand its chronic pain treatment portfolio with minimally invasive neurostimulation solutions. The proposed acquisition strengthens Medtronic’s pain management business by adding SPR Therapeutics’ peripheral nerve stimulation technology, supporting the company’s strategy to broaden non-opioid treatment options for chronic pain management.
May 2026 Haleon entered a multi-year scientific partnership with UEFA Medical to advance evidence-based approaches in topical pain management and injury-related pain relief. The collaboration focuses on improving understanding of pain management practices in sports medicine while exploring science-backed topical treatment approaches through Haleon’s pain relief portfolio.
March 2026 Electrome Corporation launched its PAINKILLER™ bioelectric pain management platform through a strategic partnership with BioElectronics Corporation. The collaboration combines Electrome’s AI-enabled bioelectric therapeutics platform with BioElectronics’ FDA-cleared electromagnetic therapy technologies to expand non-pharmacological pain management solutions.
January 2026 Pacira BioSciences entered into an agreement with LG Chem to expand access to EXPAREL® in selected Asia-Pacific markets. Under the agreement, LG Chem became the exclusive distributor of EXPAREL®, supporting broader adoption of opioid-sparing postsurgical pain management solutions in the region.